@wombat777
I have been thinking why they haven’t made a separate announcement regarding this and the methodology being used apart from calling it “preclinical”. My guess is this is obviously not financially material for the company but the other reason could be that it is with an existing research partner like Universities of New Castle, Wollongong or even Monash with whom we have partnered for pillar 3 which uses NMR-based fragment screening?
This extract from the Ann on 27/9/22 may provide the clue regarding the capabilities of the NMR program and Monash Uni.
DYOR
General Comments / Chat, page-6770
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |